R1	Has_value Arg1:T1 Arg2:T2	
R2	Has_qualifier Arg1:T4 Arg2:T5	
R3	Subsumes Arg1:T3 Arg2:T4	
R4	Has_qualifier Arg1:T6 Arg2:T8	
R5	Has_negation Arg1:T8 Arg2:T7	
*	OR T3 T6
R6	Has_multiplier Arg1:T10 Arg2:T9	
R7	Has_qualifier Arg1:T10 Arg2:T11	
R8	Has_value Arg1:T12 Arg2:T13	
R9	Has_value Arg1:T14 Arg2:T15	
R10	Has_value Arg1:T16 Arg2:T17	
R11	Has_value Arg1:T18 Arg2:T19	
R12	Has_value Arg1:T20 Arg2:T21	
R13	Has_value Arg1:T23 Arg2:T24	
R14	Has_value Arg1:T22 Arg2:T24	
R15	Has_value Arg1:T26 Arg2:T28	
R16	AND Arg1:T25 Arg2:T26	
R17	Has_value Arg1:T30 Arg2:T31	
R18	Has_value Arg1:T32 Arg2:T33	
*	OR T30 T32
R19	Has_value Arg1:T34 Arg2:T35	
R20	Has_value Arg1:T27 Arg2:T28	
R21	AND Arg1:T25 Arg2:T27	
T1	Person 0 3	Age
T2	Value 5 22	18 to75 years old
T3	Condition 55 78	advanced gastric cancer
T4	Condition 90 104	adenocarcinoma
T5	Qualifier 112 137	gastroesophageal junction
T6	Condition 155 165	metastases
T7	Negation 166 173	outside
T8	Qualifier 178 185	stomach
T9	Multiplier 347 359	at least two
T10	Procedure 366 378	chemotherapy
T11	Qualifier 264 271	Failure
T12	Measurement 390 397	ECOG PS
T13	Value 401 404	0-2
T14	Measurement 407 409	HB
T15	Value 410 419	= 90g / L
T16	Measurement 421 424	ANC
T17	Value 425 440	= 1.5 × 109 / L
T18	Measurement 442 445	PLT
T19	Value 446 460	= 80 × 109 / L
T20	Measurement 462 471	Bilirubin
T21	Value 472 509	<1.25 times the upper limit of normal
T22	Measurement 517 520	ALT
T23	Measurement 525 528	AST
T24	Value 529 539	<2.5 × ULN
T25	Condition 541 557	liver metastases
T26	Measurement 571 574	ALT
T27	Measurement 579 582	AST
T28	Value 582 590	<5 × ULN
T30	Measurement 592 600	Serum Cr
T31	Value 601 610	= 1 × ULN
T32	Measurement 611 642	endogenous creatinine clearance
T33	Value 642 651	>50ml/min
T34	Observation 682 699	expected survival
T35	Value 703 713	= 3 months
T36	Drug 733 741	apatinib
T37	Informed_consent 791 882	Patient has to voluntarily join the study and sign the Informed Consent Form for the study;
T38	Pregnancy_considerations 884 1357	Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug
